Spots Global Cancer Trial Database for A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Official Title: A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Study ID: NCT06298565
Conditions
Interventions
Study Description
Brief Summary: This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
